1.77
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Can Fite BioPharma Ltd | CANF | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.77 | 04:56:16 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 1.77 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.77 | USD |
Can Fite BioPharma Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 27.28M | 15.41M | 15.41M | $ 2.03M | $ - | -3.30 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 333.10k | $ - | 0.00% | - | - |
Can Fite BioPharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CANF Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.90 | 1.90 | 1.76 | 1.81 | 248,549 | -0.13 | -6.84% |
| 1 Month | 1.70 | 2.22 | 1.68 | 1.91 | 320,269 | 0.07 | 4.12% |
| 3 Months | 2.43 | 2.80 | 1.51 | 2.15 | 550,359 | -0.66 | -27.16% |
| 6 Months | 1.67 | 2.95 | 1.51 | 2.09 | 1,010,502 | 0.10 | 5.99% |
| 1 Year | 2.27 | 4.95 | 1.08 | 2.10 | 945,298 | -0.50 | -22.03% |
| 3 Years | 1.65 | 8.8765 | 0.38 | 2.00 | 453,906 | 0.12 | 7.27% |
| 5 Years | 3.52 | 8.8765 | 0.38 | 2.13 | 332,009 | -1.75 | -49.72% |
Can Fite BioPharma Description
| Can Fite Biofarma Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune inflammatory indications, oncology and liver diseases as well as sexual dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. The company's pipeline drugs are synthetic, specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. |
